The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology-Reference-Cited by-同舟云学术

The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology

Published:2021-09 Issue:4 Volume:73 Page:
ISSN:2724-6051
Container-title:Minerva Urology and Nephrology
language:
Short-container-title:Minerva Urol Nephrol

Author:

FERRO Matteo,LUCARELLI Giuseppe,de COBELLI Ottavio,DEL GIUDICE Francesco,MUSI Gennaro,MISTRETTA Francesco A.,LUZZAGO Stefano,BUSETTO Gian M.,BUONERBA Carlo,SCIARRA Alessandro,CONTI Simon,PORRECA Angelo,BATTAGLIA Michele,DITONNO Pasquale,MANFREDI Matteo,FIORI Cristian,PORPIGLIA Francesco,TERRACCIANO Daniela

Publisher

Edizioni Minerva Medica

Subject

Urology,Nephrology

Link

https://www.minervamedica.it/pdf.php?cod=R19Y2021N04A0442

Reference74 articles.

1. Cancer statistics, 2018

2. A history of prostate cancer treatment

3. International Variation in Prostate Cancer Incidence and Mortality Rates

4. Screening for prostate cancer with PSA testing: current status and future directions;Croswell JM;Oncology (Williston Park),2011

5. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial for Special Topics: Imaging-Based Diagnosis for Prostate Cancer—State of the Art;Diagnostics;2024-09-12

2. Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: a comprehensive analysis using Mendelian randomization, animal models, and transcriptomics;The Pharmacogenomics Journal;2024-08-07

3. Lower PHI, [-2]proPSA/fPSA and testosterone/estradiol ratios in healthy black men: preliminary results and potential implications in prostate cancer clinical management;Minerva Urology and Nephrology;2024-08

4. High Mobility Group AT-hook 2: A Biomarker Associated with Resistance to Enzalutamide in Prostate Cancer Cells;Cancers;2024-07-24

5. Urinary PSA-ZINC biomarker outperforms standard of care in early detection of prostate cancer;Minerva Urology and Nephrology;2024-06